Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Kowloon, Hong Kong.
State Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong.
J Antimicrob Chemother. 2022 Feb 2;77(2):425-432. doi: 10.1093/jac/dkab384.
Bacterial antibiotic tolerance is responsible for the recalcitrance of chronic infections. This study aims to investigate a potential drug that can effectively kill antibiotic-tolerant bacteria and evaluate the ability of this drug on the eradication of tolerant cells both in vitro and in vivo.
The in vitro effect of econazole on eradicating starvation-induced tolerant bacterial populations was studied by testing the amount of survival bacteria in the presence of econazole combining conventional antibiotics. Proton motive force (PMF) was determined after econazole treatment by DiOC2(3). Finally, mouse infection models were used to detect the ability of econazole on killing the tolerant populations in vivo.
Econazole eradicated starvation-induced tolerant cells of various bacterial species within 24 or 96 h when used in combination with conventional antibiotics. Moreover, mouse survival rate drastically increased along with the decrease of in vivo bacterial count after treatment of infected mice with the econazole and ceftazidime combination for 72 h. PMF was found to have dissipated almost completely in econazole-treated cells.
Econazole could act in combination with conventional antibiotics to effectively eradicate bacterial tolerant cells. The combined use of econazole and ceftazidime was shown to be effective for eradicating tolerant cells in a mouse infection model. The ability of econazole to eradicate tolerant cells was due to its ability to cause dissipation of bacterial transmembrane PMF. Econazole-mediated PMF disruption is a feasible strategy for the treatment of chronic and recurrent bacterial infections.
细菌对抗生素的耐受性是导致慢性感染难以治愈的原因。本研究旨在探索一种潜在的药物,能够有效杀死耐抗生素的细菌,并评估该药物在体外和体内清除耐受细胞的能力。
通过检测在存在依康唑的情况下常规抗生素杀灭饥饿诱导的耐受细菌群体的存活细菌数量,研究依康唑消除饥饿诱导的耐受细菌群体的体外效果。依康唑处理后,用 DiOC2(3)测定质子动力势(PMF)。最后,使用小鼠感染模型来检测依康唑在体内杀灭耐受群体的能力。
依康唑与常规抗生素联合使用,可在 24 或 96 小时内消除各种细菌的饥饿诱导的耐受细胞。此外,在用依康唑和头孢他啶联合治疗感染小鼠 72 小时后,随着体内细菌数量的减少,小鼠的存活率大大提高。发现在依康唑处理的细胞中 PMF 几乎完全消散。
依康唑可与常规抗生素联合使用,有效清除细菌耐受细胞。依康唑和头孢他啶的联合使用在小鼠感染模型中显示出有效清除耐受细胞的能力。依康唑清除耐受细胞的能力归因于其导致细菌跨膜 PMF 耗散的能力。依康唑介导的 PMF 破坏是治疗慢性和复发性细菌感染的一种可行策略。